Certara Identified as Leader in AI-Powered Predictive Toxicology Market
Market research indicates that Certara, Inc. held a 4% share of the global artificial intelligence in predictive toxicology market in 2025.
Stocks · News reference
'HHS launches project to speed up clinical trials' - Axios
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026
Certara, Inc. has announced it will release its financial results for the third quarter of 2026 before the market opens on November 5, 2026.
Keybanc Maintains Overweight on Certara, Raises Price Target to $12
TD Cowen Maintains Buy on Certara, Raises Price Target to $11
TD Cowen analyst Brendan Smith maintains Certara (NASDAQ:CERT) with a Buy and raises the price target from $9 to $11.
Fortrea to Participate in Jefferies Global Healthcare Conference
Fortrea announced that its executive leadership team will participate in the upcoming Jefferies Global Healthcare Conference in London.
포트리아와 오미코, 바이오마커 기반 항암 신약 개발 발전 위한 협력 추진
Fortrea, a leading clinical research organization, has partnered with Omico, Australia's precision oncology testing and clinical trial matching organization, to accelerate biomarker-based cancer research in Australia. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve patient-trial matching, enhance site selection efficiency, and expand access to precision oncology research globally.